FTC gives Lilly a go-ahead for Novartis animal health unit deal; Novartis snags EU approval for glaucoma treatment;

@FiercePharma: Pfizer turns the sex talk toward 50-ish women with menopause awareness push. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Cubist has its Zerbaxa OK. Can Merck make the launch justify its $9.5B buyout? Article | Follow @CarlyHFierce

> The Federal Trade Commission cleared Eli Lilly's ($LLY) $5.4 billion deal for Novartis' ($NVS) animal health unit as long as Lilly sells its Sentinel line of products for treating heartworm in dogs. Story

> Novartis scored EU approval for its Travatan eye drop treatment for adult patients with glaucoma. More (sub. req.)

> Novartis and Vanda Pharmaceuticals settled a licensing dispute over schizophrenia drug Fanapt. Story

> Johnson & Johnson ($JNJ) is planning to roll out a daily disposable multifocal lens product next year. More

> GlaxoSmithKline ($GSK) and partner Ligand Pharmaceuticals ($LGND) submitted an application for a new indication of Promacta for pediatric patients 6 years old and older with chronic immune (idiopathic) thrombocytopenia (ITP). Release

> South Africa's Cipla Medpro won a 2 billion rand ($173 million) contract to supply antiretroviral drugs for the next three years to the government's anti-AIDS program. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Asante files for $45M IPO to market cheap, easy insulin pump. More | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ interview comments: NIH launches crowdsourcing challenge to commercialize its neurological medical devices. Report | Follow @VarunSaxena2

@EmilyWFierce: Check out @FierceBiotech's latest special report for this year's biotech winners and losers. More | Follow @EmilyWFierce

> Study: Devices for obstructive sleep apnea could improve symptoms of depression. Article

> Trio of med techs file IPOs to raise a total of up to almost $140M. Story

Biotech News

@FierceBiotech: New special report: Best and worst 2014 biotech performers on Wall Street. Feature | Follow @FierceBiotech

@JohnCFierce: Astellas adds to deal spree with expanded $675M-plus Cytokinetics pact. Article | Follow @JohnCFierce

@DamianFierce: $ABBV's Viekira pitch includes this boomer-focused quiz thing on Facebook, featuring rotary phones and candy paper. More | Follow @DamianFierce

> J&J inks an antibody discovery deal with Sevion. Item

> Vanda settles its squabble with Novartis and pockets $25M for its trouble. Story

> Medivation buys into PD-1, picking up where Teva left off. Article

> Ariad flips Iclusig's Asian rights to Otsuka for $77.5M-plus. Report

Biotech Research News

> Northwestern team claims they have found the right way to ID Alzheimer's early on. Report

> New research points to a key driver--and new drug target--behind hepatitis infections. More

> Brown U dean points to a possible suspect driving metastasis. Article

> Stem cell investigator resigns in wake of controversy. Item

> J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration. Story

Pharma Manufacturing News

> Merck, NewLink nab $30M from BARDA to help manufacture Ebola vax. Item

> Bayer picks Cardinal Health to manufacture Xofigo in U.S. News

> Fujifilm becomes part of U.S. pandemic defense with deal for Kalon Biotherapeutics. More

> India warns Egyptian companies claiming to have Sovaldi for sale. Article

> Fresenius closes out recall started two years ago. Story

And Finally… The Indian government is slashing its 2014/2015 healthcare budget by nearly 20% due to fiscal strains. Story

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.